This is a type of cancer that starts in immature nerve cells, usually in the adrenal glands or along the spine. It's most common in babies and young children. Neuroblastoma can grow quickly and spread to other parts of the body. Treatment depends on the stage and location of the cancer.
Every report comes from a Lived member, sent anonymously.
Have you had Chemotherapy infusion for Neuroblastoma?
Neuroblastoma is a cancer that starts in neuroblasts, immature nerve cells that normally mature into part of the nervous system that runs automatic body functions. It most often begins in the adrenal glands, which sit on top of the kidneys, but it can also start along nerve tissue in the neck, chest, abdomen or pelvis. It is the most common cancer in babies under 1 year old, and most children are diagnosed before age 5. It is rare after age 10. Neuroblastoma behaves very differently from one child to another. In some infants the tumor shrinks or disappears on its own. In other children it grows quickly and has already spread to the bones, bone marrow, liver or lymph nodes by the time it is found. Much of the work after diagnosis is figuring out which kind a child has, because that decides how much treatment is needed. Symptoms usually come from the tumor pressing on nearby tissue or from cancer that has spread. A swollen belly or a lump in the abdomen, neck or chest is common. Spread to bone can cause bone pain, limping or a refusal to walk, and spread to the bones around the eyes can cause bulging eyes or dark bruising around them. Infants sometimes have small bluish bumps under the skin. A tumor near the spine can press on the spinal cord and cause weakness. Less often, the tumor releases hormones that cause high blood pressure, sweating or severe watery diarrhea, or triggers an immune reaction called opsoclonus-myoclonus-ataxia, with rapid jerky eye movements, muscle twitches and unsteadiness.
Neuroblastoma arises from changes in the genes that control how developing nerve cells grow and mature. In most children these changes happen by chance, and nothing the family did or could have done caused them. There is no known lifestyle or environmental trigger. A small share of cases are inherited. Variants in the ALK or PHOX2B genes passed from a parent raise the risk, and children who carry them tend to be diagnosed younger and sometimes have more than one tumor. Certain genetic syndromes, including Costello syndrome, Noonan syndrome, neurofibromatosis type 1 and Li-Fraumeni syndrome, are also linked to a higher risk. When a family history or a child's diagnosis suggests an inherited form, genetic counseling can explain whether testing makes sense for siblings and other relatives. Children known to carry a risk variant are usually checked regularly with ultrasound and urine tests during early childhood.
Diagnosis starts with a physical exam and a history of the child's symptoms. Imaging, usually a CT or MRI scan, shows where the tumor is and whether it involves nearby organs, blood vessels or the spinal canal. An MIBG scan uses a small amount of a radioactive tracer that neuroblastoma cells absorb, so it can show the main tumor and any spread to bone or elsewhere. The same scan is repeated later to see how well treatment is working. Most neuroblastomas release breakdown products of stress hormones (catecholamines) into the urine, so a urine test for these substances is a useful clue and can also be tracked over time. Blood tests check blood counts and markers such as lactate dehydrogenase, an enzyme that tends to be higher when the cancer is more active. A biopsy, a sample of the tumor examined under a microscope, confirms the diagnosis, and bone marrow samples taken with a needle from the hip bone show whether the cancer has reached the marrow. Some very young infants with small adrenal tumors may not need a biopsy at all. The biopsy also supplies tissue for tests that shape treatment. One of the most important is MYCN amplification, meaning the tumor carries many extra copies of a gene that drives growth; tumors with it tend to grow and spread faster. Doctors combine these tumor features with the child's age, how the cells look under the microscope, and the stage (whether the tumor is in one area or has spread) to place each child in a low-, intermediate- or high-risk group.
Treatment is planned by a pediatric cancer team and is matched to the risk group. The aim is to give enough treatment to control the cancer while sparing children with favorable disease the long-term effects of therapy they do not need. For low-risk neuroblastoma, surgery to remove the tumor is often the only treatment needed, followed by monitoring. Some infants with small tumors or favorable features are simply watched closely with scans and urine tests, because the tumor may shrink or disappear without treatment. Intermediate-risk disease is usually treated with a limited number of chemotherapy cycles to shrink the tumor, sometimes followed by surgery. Radiation is used only occasionally in these groups, for example when a tumor keeps growing or threatens the spinal cord. High-risk neuroblastoma needs intensive treatment over roughly a year or more, given in phases. It begins with several rounds of combination chemotherapy and surgery to remove as much of the main tumor as possible. Next comes high-dose chemotherapy, which destroys the bone marrow along with remaining cancer cells, followed by stem cell rescue: the child's own blood-forming stem cells, collected earlier, are returned to rebuild the marrow. Radiation is aimed at the original tumor site. The final phase uses immunotherapy with dinutuximab (Unituxin), an antibody that marks neuroblastoma cells for the immune system to attack, given with immune-boosting medicines and isotretinoin, a vitamin A-related drug that pushes remaining cancer cells to mature. Dinutuximab infusions are given in the hospital and often cause significant nerve pain, so strong pain medicine is given alongside them. Afterward, some children take eflornithine (Iwilfin), a daily tablet approved to lower the chance of the cancer coming back. If neuroblastoma does not respond or returns, options include further chemotherapy combined with antibody therapy, targeted radiation delivered by MIBG itself, and clinical trials. Because childhood cancers are rare, many children are treated within clinical trials even at first diagnosis.
The outlook depends heavily on the risk group. According to the American Cancer Society, more than 95% of children with low-risk neuroblastoma and about 95% with intermediate-risk disease are alive five years after diagnosis, and many are cured. For high-risk neuroblastoma the figure is around 60%. These are averages from children treated years ago and cannot predict how one child will do. For children with low-risk disease, life may return to normal fairly quickly after surgery or a period of monitoring. High-risk treatment is very different: families spend long stretches in the hospital, children face low blood counts and infection risk, and school, work and family routines are disrupted for a year or more. Social workers, child life specialists and psychologists are usually part of the team to help children and parents cope, and support for siblings matters too. After treatment, children have regular checkups, urine tests and scans to watch for the cancer coming back. Survivors, especially those who received intensive therapy, need long-term follow-up for late effects, which can include hearing loss, slower growth, dental problems, thyroid or heart issues, learning difficulties and, rarely, a second cancer years later. Children who had opsoclonus-myoclonus-ataxia often do well against the cancer itself but may have lasting problems with movement, learning or behavior that need ongoing support.
See a pediatrician about a lump or swelling in the belly, neck or chest, ongoing bone pain or limping, bulging eyes or bruising around the eyes without an injury, or bluish bumps under an infant's skin. These signs usually have other causes, but they warrant an exam. During cancer treatment, call the care team right away for a fever, chills, or redness or swelling where a central line enters the skin. Chemotherapy lowers the body's defenses, and infections can become serious quickly; follow the specific fever instructions the team gives you. New weakness in the legs or arms, trouble walking, or new loss of bladder or bowel control in a child with known or suspected neuroblastoma can mean the tumor is pressing on the spinal cord. This needs emergency care, because nerve function is more likely to recover when treatment starts quickly.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Neuroblastoma is like, what's helped you, or ask the community a question.